SkinVision, founded in 2011 and headquartered in The Netherlands, presents a compelling case for venture capital investment with its innovative mobile application designed to detect skin cancer early. By leveraging a highly accurate AI-based algorithm, the app has gained trust from over 3 million users globally, claiming a clinically validated 95% sensitivity in identifying signs of common skin cancers.
The company is addressing a significant healthcare challenge, as skin cancer affects 1 in 5 people during their lifetime. Early detection significantly increases treatment success rates, a need that SkinVision aims to meet by democratizing access to reliable and convenient self-exam tools.
Despite the last known investment dated 01 February 2020, SkinVision's ongoing mission to eradicate skin cancer mortality presents a growth opportunity for investors to align with a purpose-driven venture that aims to save 250,000 lives in the coming decades.